Abstract
10726 Background: IA infusion of CT increases drug concentrations within a tumor. We investigated if it is effective in BC patients (pts) with locally advanced disease or liver metastases. Methods: Twenty-five pts were treated with IA CT using angiographic technique in the Department of Medical Oncology, Morgagni-Pierantoni Hospital in Forlì. Pts received a short IA infusion through the proper hepatic artery (liver metastases) or the internal mammary artery (locally advanced disease). Drugs were: Epirubicin (EPI) 30 mg/m2, Mitomycin-c (MMC) 7 mg/m2 and 5-fluoruracil (5FU) 1000 mg on day 1 every 21 days. EPI was not administered in anthracycline pretreated pts. Results: Median age was 54.3 years (31–75 years) and ECOG Performance Status (PS) was ≤2. Nine pts had liver metastases and 16 had locally advanced disease. Twenty-three (96%) of the 25 pts had received adjuvant treatment (21 CT, 7 endocrine therapy), 20 (80%) had had at least one treatment for metastatic disease (20 CT, 11 endocrine therapy, 8 radiotherapy), and 11 pts (40%) had received concomitant therapy (3 CT and 8 endocrine). Fifteen pts were anthracycline-naïve. A total of 88 angiographic sessions were carried out, with a median number of 3.5 cycles per patient (1–8 cycles). One transitory ischaemic attack occurred during angiographic procedure . No other serious complications were observed. The only cases of toxicity higher than grade 2 were one grade III neutropenia and one grade IV thrombocytopenia. A dose reduction was necessary in 4 pts (2 due to PS, 1 to toxicity and 1 to pre-treatment) and treatment was interrupted in 4 pts (2 due to PS, 1 to early progression and 1 to technical problems). Among the 19 pts assessable for response, 13 (68%) had a partial response, 2 (11%) showed stable disease and 4 (21%) progressed. Median time to progression and median overall survival will be given. Conclusions: Our results suggest that IA CT may play a role in the treatment of advanced pre-treated BC pts. No significant financial relationships to disclose.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
